Response to: Second-line treatment of non-small-cell lung cancer with wild-type EGFR status. What is the best approach?

Eitemau Tebyg

• Second-line treatment of non-small-cell lung cancer with wild-type EGFR status. What is the best approach?
  gan: Elghissassi, Ibrahim, et al.
  Cyhoeddwyd: (2016)
• An exploratory comparative analysis of tyrosine kinase inhibitors or docetaxel in second-line treatment of EGFR wild-type non-small-cell lung cancer: a retrospective real-world practice review at a single tertiary care centre
  gan: Ma, K., et al.
  Cyhoeddwyd: (2015)
• Second-line erlotinib in an EGFR mutation-negative patient with non-small-cell lung cancer
  gan: Hirsh, Vera
  Cyhoeddwyd: (2012)
• Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors versus single agent chemotherapy as second‐line treatment for non–small‐cell lung cancer wild‐type or unknown status for EGFR
  gan: Créquit, Perrine, et al.
  Cyhoeddwyd: (2018)
• Intrapartum management of twin gestation: what is best for the second and the small?
  gan: Gandhi, J., et al.
  Cyhoeddwyd: (1983)